Compare VAI & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAI | NSRX |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0M | 37.1M |
| IPO Year | 2017 | 2024 |
| Metric | VAI | NSRX |
|---|---|---|
| Price | $1.66 | $2.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | ★ 58.5K | 15.0K |
| Earning Date | 11-18-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,546,127.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.56 | $1.98 |
| 52 Week High | $2.91 | $9.50 |
| Indicator | VAI | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.75 | 35.77 |
| Support Level | N/A | $2.04 |
| Resistance Level | $2.34 | $3.61 |
| Average True Range (ATR) | 0.30 | 0.30 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 13.48 | 1.39 |
Valor Energy Inc, formerly Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with a lease term of no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.